Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries
Jamsheer Talati(Aga Khan University), Mohammad Zeeshan(Aga Khan University), Wajahat Aziz(Aga Khan University), Raziuddin Biyabani(Aga Khan University), Shoaib Rao(Aga Khan University), Lena Jafri(Aga Khan University), Aysha Habib Khan(Aga Khan University), Iqbal Azam(Aga Khan University), Jamil Ahmed(Scarborough General Hospital), Amanullah Memon(Aga Khan University), Sally‐Anne Hulton(Birmingham Children's Hospital), Zafar Nazir(Aga Khan University), Sander F. Garrelfs(Emma Kinderziekenhuis), Saqib Hamid Qazi(Aga Khan University)
Cited by 22
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
|Kidney International|2019|103
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
|Kidney International|2021|90
Genetic assessment in primary hyperoxaluria: why it matters
|Pediatric Nephrology|2022|57